ClinicalTrials.gg
CompletedNCT01539083VCATUpdated Feb 4, 2025Results posted

Velcade (Bortezomib) Consolidation After Transplant

A Phase 3 interventional study of Thalidomide and Bortezomib in Multiple Myeloma, sponsored by Janssen Scientific Affairs, LLC. Completed at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing thalidomide in Multiple Myeloma — 2 open to participants now, 6 under way, 2 of them phase 3. Thalidomide · Multiple Myeloma.

Enrollment
22nd of 87
256 · median 80
Started
2012
with 1 other
Phase 3
32 of 93
none open now
Registered
77th of 93
by date

Among the 93 studies testing thalidomide in Multiple Myeloma, this one is the 22nd largest by enrollment of the 87 interventional ones that give a count, is one of 2 that started in 2012, is one of 32 in phase 3, and was the 77th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

2 of the 93 studies testing thalidomide in Multiple Myeloma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About thalidomide

Thalidomide: first FDA approval 1998 (THALOMID), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing thalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to determine if bortezomib when added to consolidation treatment with thalidomide and prednisolone leads to an improved response in patients with multiple myeloma who have undergone autologous stem cell transplant and initial treatment with bortezomib, cyclophosphamide, and dexamethasone.

Read the detailed description

This is an open-label (patients will know the identity of study treatments), randomized (patients will be assigned by chance to different treatments) study of bortezomib administered as consolidation therapy (therapy given once a remission is achieved) with thalidomide and prednisolone versus thalidomide and prednisolone alone in previously untreated patients with multiple myeloma. Multiple myeloma is a cancer of your plasma cells, a type of white blood cell present in your bone marrow. Patients in this study will receive initial therapy with bortezomib, cyclophosphamide, and dexamethasone (referred to as VCD induction therapy) and will undergo autologous stem cell transplant (ASCT) (a procedure where patients receive an infusion of immature blood cells [stem cells] from their own body to replenish the body's supply of healthy blood-forming cells) before randomization to one of two treatments: Treatment A (thalidomide for up to 12 months or until disease progression and prednisolone on alternate days continued indefinitely or until disease progression) or Treatment B (bortezomib for 32 weeks in addition to thalidomide up to 12 months or until disease progression and prednisolone on alternate days, continued indefinitely or until disease progression.

Throughout the study, the patient's response to therapy will be assessed according to protocol-defined efficacy evaluations and by implementing defined disease response criteria (International Myeloma Working Group [IMWG] criteria). Safety will be evaluated throughout the study. Follow up for progression-free survival (PFS) and overall survival (OS) will be conducted from time of randomization to 3 years post-randomization.

Two interim analyses are planned. The final analysis will be conducted after all patients have completed 12-month consolidation treatment phase or discontinued. The primary endpoint of number and percent of patients with complete response and very good partial response defined by IMWG criteria for multiple myeloma will be examined in the interim and final analyses after approximately 12 months of consolidation therapy. At the completion of the study, updated analyses of PFS and OS will be performed.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Bortezomib
  • VELCADE
  • Consolidation therapy
  • Subcutaneous
  • Thalidomide
  • Prednisolone
  • Autologous stem cell transplant (ASCT)
  • VELCADE, cyclophosphamide, dexamethasone (VCD) induction therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously diagnosed with multiple myeloma based on international myeloma working group (IMWG) criteria.and meet all of the following; Serum M-protein greater than or equal to (>=) 1 gram per deciliter (g/dL) (>=10 gram per liter); Urine M-protein >=200 milligram (mg) per 24 hour and Serum Free Light chain (FLC) assay: Involved FLC Level >=10 mg/dL (>=100 mg/L) provided serum FLC ratio is normal
  • Meet the pretreatment laboratory criteria as specified in the study protocol at and within 21 days before baseline (Day 1 of Cycle 1, before bortezomib administration for induction).
  • Have status 0-2.
  • Men and women must practice an appropriate method of as specified in the study protocol from signing of the form though to the 12-month visit/early termination visit.

Exclusion criteria

Exclusion criteria:

  • Has previously received treatment for multiple myeloma (including prior therapy with radiation or pulsed dexamethasone) as specified in the study protocol.
  • Has a history of any other within 5 years before enrolment as specified in the study protocol.
  • Has had major surgery as specified in the study protocol within 30 days before enrolment.
  • Had a myocardial infarction within 6 months of enrolment or has (NYHA) Class III or IV heart failure (or other cardiac medical history as specified in the study protocol).
  • Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]

    Bortezomib (Velcade) 1.3 milligram per square meter (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m\^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.

    Drug: Bortezomib · Drug: Cyclophosphamide · Drug: Dexamethasone

  • Experimental
    Thalidomide + Prednisolone [TP Consolidation]

    Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.

    Drug: Thalidomide · Drug: Prednisolone

  • Experimental
    Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]

    Bortezomib 1.3 mg/m\^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.

    Drug: Thalidomide · Drug: Bortezomib · Drug: Prednisolone

Interventions

06

What researchers measure

Primary outcomes

  1. Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12

    CR as per IMWG criteria is defined as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow. VGPR as per IMWG criteria is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90 percent or greater reduction in serum M-protein plus urine M-protein level \<100 milligram (mg) per 24 hours.

    Time frame: Month 12

Secondary outcomes

  1. Consolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12

    CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow.

    Time frame: Months 3, 6, 9 and 12

  2. Consolidation Phase: Percentage of Participants With Stringent Complete Response (sCR) at Months 3, 6, 9 and 12

    sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow. CR is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow.

    Time frame: Months 3, 6, 9 and 12

  3. Progression Free Survival (PFS)

    PFS, calculated as the time between randomization to disease progression or death (regardless of cause), whichever occurred first. Progressive disease as per IMWG criteria: increase of \>= 25 percent from lowest response level in Serum M-component and/or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]) Urine M-component and/or (the absolute increase must be \>=200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \>10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be \>=10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 millimole per liter (mmol/L) that can be attributed solely to the plasma cell proliferative disorder.

    Time frame: Baseline until progressive disease (up to 5 years)

  4. Disease-free Survival (DFS)

    DFS, defined as the duration from the start of CR to the time of relapse from CR. DFS applied only to participants in CR. CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow. Relapse from CR: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of \>= 5 percent plasma cells in the bone marrow; appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcaemia).

    Time frame: Up to 5 years

  5. Overall Survival (OS)

    OS was defined as the time between randomization and death. Death of a participant regardless of the cause was considered as an event.

    Time frame: Up to 5 years

  6. Consolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase

    The assessment of quality of life-6D (AQoL-6D) is a multi-attribute health-related quality of life instrument (QoL). It comprises dimension scores for independent living, relationships, mental health, coping, pain, senses, and utility score for AQol-6D. Each scale ranges between 1 (best QoL) and -0.04 (worst possible QoL).

    Time frame: Baseline, Month 12

  7. Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase

    Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) consists of 10 items and evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. 1 FACT/GOG-NTX total score has a range of 0 to 108 with a higher score indicating better quality of life.

    Time frame: Baseline, Month 12

07

Results

Posted Feb 9, 2017

Participant flow

Before Randomization (VCD Induction)
Participant flow — Before Randomization (VCD Induction)
MilestoneBortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)Thalidomide + Prednisolone (TP Consolidation)Bortezomib + Thalidomide + Prednisolone (VTP Consolidation)
Started25600
Treated25400
Completed20300
Not completed5300
Withdrew: Withdrawal by subject400
Withdrew: Adverse event1400
Withdrew: Death600
Withdrew: Protocol violation200
Withdrew: Physician decision1400
Withdrew: Progressive disease800
Withdrew: Other500
After Randomization (TP and VTP)
Participant flow — After Randomization (TP and VTP)
MilestoneBortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)Thalidomide + Prednisolone (TP Consolidation)Bortezomib + Thalidomide + Prednisolone (VTP Consolidation)
Started0100103
Safety population099103
Completed07980
Not completed02123
Withdrew: Physician decision001
Withdrew: Other011
Withdrew: Adverse event011
Withdrew: Lost to follow-up022
Withdrew: Withdrawal by subject054
Withdrew: Progressive disease063
Withdrew: Death0611

Outcome measures

PrimaryConsolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12

CR as per IMWG criteria is defined as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow. VGPR as per IMWG criteria is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90 percent or greater reduction in serum M-protein plus urine M-protein level \<100 milligram (mg) per 24 hours.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12
percentage of participantsThalidomide + Prednisolone [TP Consolidation]Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]
Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 1281.392.9
SecondaryConsolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12

CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow.

Time frame:
Months 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Consolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12
percentage of participantsThalidomide + Prednisolone [TP Consolidation]Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]
Month 336.536.7
Month 644.844.9
Month 949.052.0
Month 1251.053.1
SecondaryConsolidation Phase: Percentage of Participants With Stringent Complete Response (sCR) at Months 3, 6, 9 and 12

sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow. CR is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow.

Time frame:
Months 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Consolidation Phase: Percentage of Participants With Stringent Complete Response (sCR) at Months 3, 6, 9 and 12
percentage of participantsThalidomide + Prednisolone [TP Consolidation]Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]
Month 320.823.5
Month 627.128.6
Month 926.030.6
Month 1226.028.6
SecondaryProgression Free Survival (PFS)

PFS, calculated as the time between randomization to disease progression or death (regardless of cause), whichever occurred first. Progressive disease as per IMWG criteria: increase of \>= 25 percent from lowest response level in Serum M-component and/or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]) Urine M-component and/or (the absolute increase must be \>=200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \>10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be \>=10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 millimole per liter (mmol/L) that can be attributed solely to the plasma cell proliferative disorder.

Time frame:
Baseline until progressive disease (up to 5 years)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsThalidomide + Prednisolone [TP Consolidation]Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]
Progression Free Survival (PFS)22.05 (18.46 to 25.49)22.51 (18.56 to 24.15)
SecondaryDisease-free Survival (DFS)

DFS, defined as the duration from the start of CR to the time of relapse from CR. DFS applied only to participants in CR. CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow. Relapse from CR: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of \>= 5 percent plasma cells in the bone marrow; appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcaemia).

Time frame:
Up to 5 years
Reported as:
Median · months
Disease-free Survival (DFS)
monthsThalidomide + Prednisolone [TP Consolidation]Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]
Disease-free Survival (DFS)18.53 (11.24 to 23.36)13.37 (10.18 to 20.96)
SecondaryOverall Survival (OS)

OS was defined as the time between randomization and death. Death of a participant regardless of the cause was considered as an event.

Time frame:
Up to 5 years
Reported as:
Median · months
Overall Survival (OS)
monthsThalidomide + Prednisolone [TP Consolidation]Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryConsolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase

The assessment of quality of life-6D (AQoL-6D) is a multi-attribute health-related quality of life instrument (QoL). It comprises dimension scores for independent living, relationships, mental health, coping, pain, senses, and utility score for AQol-6D. Each scale ranges between 1 (best QoL) and -0.04 (worst possible QoL).

Time frame:
Baseline, Month 12
Reported as:
Mean · units on a scale
Consolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase
units on a scaleThalidomide + Prednisolone [TP Consolidation]Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]
Independent Living0.15 ± 0.3350.14 ± 0.397
Relationships0.06 ± 0.3000.05 ± 0.296
Mental Health0.18 ± 0.3190.18 ± 0.270
Coping0.08 ± 0.2780.05 ± 0.237
Pain0.20 ± 0.3730.20 ± 0.395
Senses0.03 ± 0.1400.00 ± 0.137
AQoL-6D Utility score0.11 ± 0.2160.11 ± 0.213
SecondaryConsolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase

Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) consists of 10 items and evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. 1 FACT/GOG-NTX total score has a range of 0 to 108 with a higher score indicating better quality of life.

Time frame:
Baseline, Month 12
Reported as:
Mean · units on a scale
Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase
units on a scaleThalidomide + Prednisolone [TP Consolidation]Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]
Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase2.9 ± 19.681.0 ± 19.69

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)—88/254 (34.6%)233/254 (91.7%)
Thalidomide + Prednisolone (TP Consolidation)—22/99 (22.2%)95/99 (96%)
Bortezomib + Thalidomide + Prednisolone (VTP Consolidation)—28/103 (27.2%)96/103 (93.2%)
Most frequent serious events
Showing 10 of 98
Most frequent serious events
EventBortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)Thalidomide + Prednisolone (TP Consolidation)Bortezomib + Thalidomide + Prednisolone (VTP Consolidation)
PneumoniaInfections and infestations5/2546/997/103
PyrexiaGeneral disorders12/2541/993/103
Febrile NeutropeniaBlood and lymphatic system disorders11/2540/990/103
Herpes ZosterInfections and infestations0/2542/992/103
Lobar PneumoniaInfections and infestations1/2542/990/103
Respiratory Tract InfectionInfections and infestations1/2542/991/103
Back PainMusculoskeletal and connective tissue disorders4/2542/990/103
Lower Respiratory Tract InfectionInfections and infestations4/2541/992/103
Rhinovirus InfectionInfections and infestations0/2540/992/103
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders2/2541/992/103
Most frequent other events
Showing 10 of 48
Most frequent other events
EventBortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)Thalidomide + Prednisolone (TP Consolidation)Bortezomib + Thalidomide + Prednisolone (VTP Consolidation)
ConstipationGastrointestinal disorders91/25438/9929/103
Peripheral Sensory NeuropathyNervous system disorders62/25438/9938/103
Upper Respiratory Tract InfectionInfections and infestations29/25432/9939/103
NauseaGastrointestinal disorders82/25410/9912/103
Neuropathy PeripheralNervous system disorders34/25424/9930/103
Weight IncreasedInvestigations7/25426/9917/103
FatigueGeneral disorders61/25418/9916/103
InsomniaPsychiatric disorders56/25422/9913/103
Oedema PeripheralGeneral disorders44/25415/9916/103
NeuralgiaNervous system disorders19/25414/9916/103

Baseline characteristics

Baseline population was defined as all enrolled participants who received at least 1 non-zero dose of any study drug in the induction phase.

Age, Continuous
Age, Continuous(years)Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)
Mean57.8 ± 7.76
Sex: Female, Male
Sex: Female, Male(Participants)Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)
Female109
Male145
Region of Enrollment
Region of Enrollment(Participants)Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)
Australia207
China17
Republic of Korea30
08

Study locations

23 sites
  • Adelaide, Australia
  • Camperdown, Australia
  • Geelong, Australia
  • Greenslopes, Australia
  • Heidelberg, Australia
  • Herston, Australia
  • Malvern, Australia
  • Melbourne, Australia
  • Nedlands, Australia
  • Newcastle, Australia
  • Prahran, Australia
  • Sydney, Australia
  • Westmead, Australia
  • Woodville South, Australia
  • Woolloongabba, Australia
  • Beijing, China
  • Guangzhou, China
  • Shanghai, China
  • Tianjin, China
  • Busan, Korea, Republic of
  • Daegu, Korea, Republic of
  • Jeollanam-do, Korea, Republic of
  • Ulsan, Korea, Republic of
09

References and documents

Publications

  • Horvath N, Spencer A, Kenealy M, Joshua D, Campbell PJ, Lee JJ, Hou J, Qiu L, Kalff A, Khong T, Londhe A, Siggins S, van Kooten Losio M, Eisbacher M, Prince HM. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Leuk Lymphoma. 2019 Sep;60(9):2122-2133. doi: 10.1080/10428194.2019.1579322. Epub 2019 Feb 19. PubMed 30777794 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Dec 2015, 47 months.

Results were first posted in Feb 2017, 1 year 1 month after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 47 months is close to that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2011
First posted
Feb 27, 2012
StartActual
Jan 13, 2012
Primary completionActual
Dec 30, 2015
CompletionActual
Jan 9, 2018
Results first posted
Feb 9, 2017
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01539083
Responsible party
Sponsor
First posted
Feb 27, 2012
Start date
Jan 13, 2012
Primary completion
Dec 30, 2015
Completion
Jan 9, 2018
Results posted
Feb 9, 2017
Last update
Feb 4, 2025

Study contacts

Janssen Asia-Pacific Medical Affairs Clinical Trial
study director · Janssen Asia-Pacific Medical Affairs

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Thalidomide · Bortezomib · Cyclophosphamide · Dexamethasone · Prednisolone

Start the discussion